Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Akcea Therapeutics Inc (AKCA) USD0.001

Sell:$18.08 Buy:$18.09 Change: $0.85 (4.49%)
NASDAQ:0.83%
Market closed |  Prices as at close on 18 October 2019 | Switch to live prices |
Sell:$18.08
Buy:$18.09
Change: $0.85 (4.49%)
Market closed |  Prices as at close on 18 October 2019 | Switch to live prices |
Sell:$18.08
Buy:$18.09
Change: $0.85 (4.49%)
Market closed |  Prices as at close on 18 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).

Contact details

Address:
22 Boston Wharf Rd Fl 9
BOSTON
02210-1838
United States
Telephone:
+1 (617) 2070202
Website:
akceatx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AKCA
ISIN:
US00972L1070
Market cap:
$1.68 billion
Shares in issue:
93.03 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Christopher Gabrieli
    Chairman of the Board
  • Damien McDevitt
    Interim Chief Executive Officer, Director
  • Michael Maclean
    Chief Financial Officer
  • Louis O'Dea
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.